Correlation Between NewAmsterdam Pharma and Entera Bio

Can any of the company-specific risk be diversified away by investing in both NewAmsterdam Pharma and Entera Bio at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NewAmsterdam Pharma and Entera Bio into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between NewAmsterdam Pharma and Entera Bio, you can compare the effects of market volatilities on NewAmsterdam Pharma and Entera Bio and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NewAmsterdam Pharma with a short position of Entera Bio. Check out your portfolio center. Please also check ongoing floating volatility patterns of NewAmsterdam Pharma and Entera Bio.

Diversification Opportunities for NewAmsterdam Pharma and Entera Bio

0.32

Correlation Coefficient

NewAmsterdam Pharma  Entera Bio

Weak diversification

The 3 months correlation between NewAmsterdam and Entera is 0.32. Overlapping area represents the amount of risk that can be diversified away by holding NewAmsterdam Pharma and Entera Bio in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Entera Bio and NewAmsterdam Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NewAmsterdam Pharma are associated (or correlated) with Entera Bio. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Entera Bio has no effect on the direction of NewAmsterdam Pharma i.e., NewAmsterdam Pharma and Entera Bio go up and down completely randomly.

Pair Corralation between NewAmsterdam Pharma and Entera Bio

Given the investment horizon of 90 days NewAmsterdam Pharma is expected to generate 4.4 times less return on investment than Entera Bio. In addition to that, NewAmsterdam Pharma is 1.24 times more volatile than Entera Bio. It trades about 0.02 of its total potential returns per unit of risk. Entera Bio is currently generating about 0.1 per unit of volatility. If you would invest  164.00  in Entera Bio on November 28, 2024 and sell it today you would earn a total of  43.00  from holding Entera Bio or generate 26.22% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

NewAmsterdam Pharma  vs.  Entera Bio

NewAmsterdam Pharma

Risk-Adjusted Performance

Very Weak

Compared to the overall equity markets, risk-adjusted returns on investments in NewAmsterdam Pharma are ranked lower than 1 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak primary indicators, NewAmsterdam Pharma may actually be approaching a critical reversion point that can send shares even higher in March 2025.

Entera Bio

Risk-Adjusted Performance

OK

Compared to the overall equity markets, risk-adjusted returns on investments in Entera Bio are ranked lower than 8 (%) of all global equities and portfolios over the last 90 days. In spite of fairly weak basic indicators, Entera Bio showed solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with NewAmsterdam Pharma and Entera Bio

The main advantage of trading using opposite NewAmsterdam Pharma and Entera Bio positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NewAmsterdam Pharma position performs unexpectedly, Entera Bio can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entera Bio will offset losses from the drop in Entera Bio's long position.

The idea behind NewAmsterdam Pharma and Entera Bio pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Equity Forecasting module to use basic forecasting models to generate price predictions and determine price momentum.